专利号:US-2003138490-A1 优先权日:2001-09-08 标 题 :Synthesis and uses of polymer gel nanoparticle networks 发明人:HU ZHIBING; LU XIHUA; GAO JUN; PONDER BILL C; JOHN JOHN ST; MORO DANIEL G 摘要:Disclosed is a new class of nanostructured polymeric materials comprising polymer gel nanoparticles that are covalently bonded through functional groups on the surfaces of neighboring particles. These nanoparticles may be prepared as suspensions in an aqueous or, non-aqueous environment. These gels have two unique and different structural networks; the primary network comprises crosslinked polymer chains in each individual particle, while the secondary network is a system of crosslinked nanoparticles. Particular polymer gel nanoparticle network compositions disclosed herein may function as carriers for controlled delivery of pharmaceuticals or other chemical agents, gel sensors and other commercial applications.
专利号:US-2006247308-A1 优先权日:1999-05-14 标 题:Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response 发明人:KATZ STANLEY E; MARTIN ALAIN 权利人:KATZ STANLEY E; MARTIN ALAIN 摘要:A method for treating the disease state in mammals caused by mammalian nasal and sinus cells involved in the inflammatory response is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.
专利号:EP-1183022-B1 优先权日:1999-05-14 标题 :Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response 发明人:KATZ STANLEY E; MARTIN ALAIN 权利人:CELLULAR SCIENCES INC 摘要:A method for treating the disease state in mammals caused by a mammalian nasal and sinus cells involved in the inflammatory responser is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.
专利号:US-7531164-B2 优先权日:2005-10-21 标 题 :Preventing bacterial or viral infectivity and composition containing infection preventing additive 发明人:DAAKA YEHIA; STAMLER JONATHAN S 权利人:UNIV DUKE 摘要:A nitric oxide synthesis inhibitor or nitric oxide scavenger is administered to prevent development of infection, to prevent development of a cancer where overstimulation of a receptor contributes to the cancer development, and to prevent loss of beta agonist responsivity and as a treatment in combination with a receptor blocker. Compositions include nitric oxide synthesis inhibitor or nitric oxide scavenger containing spermicidal compositions, nasal steroid compositions, urinary tract infection prophylaxis compositions, compositions for prophylaxis of EGFR associated cancer and human blood component(s) composition for transfusion.
专利号:US-2018230127-A1 优先权日:2015-08-13 标题 :Bicyclic-Fused Heteroaryl Or Aryl Compounds 发明人:ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; GAVRIN LORI KRIM; GOLDBERG JOEL ADAM; LEE ARTHUR; LOWE MICHAEL DENNIS; PATNY AKSHAY; PIERCE BETSY SUSAN; SAIAH EDDINE; TRZUPEK JOHN DAVID 权利人:PFIZER 摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.
专利号:US-9879022-B2 优先权日:2014-04-04 标题:Bicyclic-fused heteroaryl or aryl compounds 发明人:TRZUPEK JOHN DAVID; LEE KATHERINE LIN; BUNNAGE MARK EDWARD; HAN SEUNGIL; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; PAPAIOANNOU NIKOLAOS; PIERCE BETSY SUSAN; STROHBACH JOSEPH WALTER; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG; GAVRIN LORI KRIM; LEE ARTHUR; ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; DEHNHARDT CHRISTOPH MARTIN; SAIAH EDDINE; GOLDBERG JOEL ADAM; WANG XIAOLUN; HUANG HORNG-CHIH; VARGAS RICHARD; LOWE MICHAEL DENNIS; PATNY AKSHAY 权利人:PFIZER 摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
1: Kirtsreesakul V, Khanuengkitkong T, Ruttanaphol S. Does oxymetazoline increase the efficacy of nasal steroids in treating nasal polyposis? Am J Rhinol Allergy. 2016 May;30(3):195-200. doi: 10.2500/ajra.2016.30.4294. doi: 10.12932/AP0649.34.1.2016. doi: 10.1016/j.adaj.2015.12.008. Epub 2016 Jan 25. doi: 10.1177/0003489415617776. Epub 2015 Nov 26. 7: Nordt SP, Vivero LE, Cantrell FL. Not Just a Drop in the Bucket-Inversion of Oxymetazoline Nasal Decongestant Container Increases Potential for Severe Pediatric Poisoning. J Pediatr. 2016 Jan;168:240-1. doi: 10.1016/j.jpeds.2015.09.067. Epub 2015 Oct 30. doi: 10.2500/aap.2015.36.3879. Epub 2015 Jun 29. doi: 10.1115/1.4030825. Epub 2015 Jun 23. doi: 10.1097/DSS.0000000000000362.
合成参考文献
参考文献:10.1007/s10337-025-04390-y 摘要:Kulkarni SV, Lokhande S, Musmade BD, Bhope SG, Nagar M, Panchgalle SP, More VS. Quantification of Seven Known and Several Unknown Impurities from Fluticasone Furoate and Oxymetazoline Hydrochloride Nasal Spray Product Using RP-HPLC UV Methodology. Chromatographia. 2025 Feb 10;88(3):243–55. doi: 10.1007/s10337-025-04390-y.